As recruitment and activation of XCR1+ cDC1 in tumours is considered critical for activation of cytotoxic CD8+ T cells and immunotherapy36 we next assessed CD86 surface expression as a marker of cDC1 activation in mice treated with AZD5069/anti-PD1 therapy. This evidence concerns the gene CD86 and neoplasm.